Latest AI and machine learning research in other cancers for healthcare professionals.
BACKGROUND: Extrachromosomal circular DNA (eccDNA) is increasingly recognized as a critical driver o...
BACKGROUND: Circulating tumor DNA (ctDNA) is sometimes undetectable in liquid comprehensive genomic ...
BACKGROUND: Combination immune checkpoint inhibitors are recommended as first-line therapy for advan...
PURPOSE: To differentiate benign and malignant breast masses by extracting radiomic features from lo...
PURPOSE: Immune checkpoint blockade (ICB) benefits only a subset of sarcoma patients. Biomarkers of ...
BACKGROUND: Artificial intelligence (AI) has shown increasing potential in lung cancer imaging, part...
BACKGROUND: Age and disease stage are critical factors in guiding management in Legg-Calvé-Perthes d...
INTRODUCTION: The third most prevalent form of cancer, colorectal cancer (CRC), is associated with a...
The immune evasion that is encouraged by the tumor microenvironment (TME) is a key factor in the fai...
RATIONALE AND OBJECTIVES: Accurate staging of hepatic fibrosis is essential for guiding immunosuppre...
BACKGROUND: Clinical decision support (CDS) systems have been widely adopted in health care to enhan...
Benzo[a]pyrene (BaP), a ubiquitous environmental carcinogen predominantly found in tobacco smoke and...
Prussian blue nanoparticles (PBNPs) are a versatile platform for administering photothermal therapy ...
The global rise in steatotic liver disease poses a significant public health challenge. While non-co...
Hyperspectral imaging (HSI) is a three-dimensional imaging technique that integrates spectroscopy an...
Major depressive disorder (MDD) is a leading global health burden, yet only one-third of patients ac...
BACKGROUND & AIMS: In hepatocellular carcinoma (HCC) with cirrhosis, portal hypertension worsens out...
Ependymomas (EPN) are rare central nervous system tumors that account for approximately 10% of intra...
Multimodal profiling of inflammatory bowel disease (IBD) patient tissue and blood samples has reveal...
PURPOSE: Low-grade gliomas(LGGs) show significant clinical and molecular heterogeneity, complicating...
BACKGROUND: About 30-40% of patients with renal-cell carcinoma experience recurrence within 5 years ...